[ad_1]
BEIJING / TOKYO / SEOUL / MANILA / TAIPEI / JAKARTA / DHAKA / HANOI (Dec 11): Pfizer Inc’s trial data with its partner BioNTech SE, Moderna Inc and AstraZeneca Plc have shown that their experimental vaccines are effective in preventing the infection with the new coronavirus.
While regulatory processes are underway, few Asian countries expect to initially receive significant quantities of the vaccines. Below are the estimated delivery times, announced supply agreements, and clinical trials taking place in the region.
Australia
The country has obtained around 140 million doses: 53.8 million from AstraZeneca, 51 million from Novavax Inc, 10 million from Pfizer and 25.5 million from the COVAX distribution program.
It expects the delivery of 3.8 million doses of the AstraZeneca vaccine in January and February next year and plans to begin inoculations in March.
China
China has not announced supply agreements with Western pharmaceutical companies, which have instead partnered with private companies in the country.
AstraZeneca’s vaccine can be approved in China in mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products Co Ltd plans an annual production capacity of at least 100 million doses by the end of this year.
For the Pfizer / BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group Co Ltd is planning a phase II trial.
Tibet Rhodiola Pharmaceutical Holding Co is incorporating the Russian Sputnik V vaccine candidate and planning early and mid-stage trials in China.
China has also approved three candidate vaccines developed by Sinovac Biotech Ltd and the state-owned China National Pharmaceutical Group (Sinopharm) for emergency use, and Sinopharm expects its two candidates to get conditional approval for general use this year.
Japan
Japan has agreements to buy 120 million doses of Pfizer / BioNTech in the first half of next year and 120 million of AstraZeneca (the first 30 million will be shipped in March 2021) and 250 million of Novavax.
It is also in talks with Johnson & Johnson and has an agreement with Shionogi & Co Ltd.
Experts said that vaccine manufacturers would need to conduct at least phase I and II trials in Japan before seeking approval for their use.
South Korea
The country has agreements to buy 20 million doses each from AstraZeneca, Pfizer and Moderna and another 4 million doses from Johnson & Johnson’s Janssen, enough to cover up to 34 million people.
You will purchase additional doses for 10 million people through COVAX.
Inoculation is likely to begin in the second trimester of next year to allow time to observe possible side effects.
India
The director of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov. 23 that the candidate’s positive late state trial result will allow him to seek emergency use approval before the end of the year, before gaining approval for full introduction by February or March.
India also expects a government-backed vaccine to be released starting in February. It is also conducting a last-stage test of Sputnik V.
Taiwan
Taiwan aims to secure around 15 million doses initially, both through the COVAX scheme and through direct purchases from manufacturers, and can buy an additional 15 million doses.
The government has said it expects to start vaccinations in the first quarter of next year.
Malaysia
The Southeast Asian nation agreed to buy 12.8 million doses of the Pfizer vaccine, becoming the first country in the region to announce an agreement with the US pharmaceutical company after some expressed reservations about the need for ultra-cold storage that the vaccine requires. vaccine.
Pfizer will deliver the first batch of 1 million doses in the first quarter of next year.
The philippines
The archipelago announced a deal on November 27 for 2.6 million doses of the AstraZeneca vaccine and is discussing a possible million more, covering about 1% of a population of 108 million people.
He’s also looking for 20-50 million doses of Sinovac and is in talks with others, including Pfizer.
Vaccine manufacturers can seek approval from Philippine regulators even if no clinical trials are conducted in the country.
Indonesia
The most populous country in Southeast Asia has obtained 125.5 million doses of Sinovac, 30 million from Novavax, is in talks with AstraZeneca and Pfizer to buy 50 million doses each and hopes to obtain 16 million COVAX.
Indonesia is testing the Sinovac vaccine and preparing mass vaccination for medical personnel and other front-line workers to begin in late January.
Vietnam
A government official said that COVAX vaccines would cover only 20% of the population and the country is likely to have a chance to get separate deals soon as demand is so high.
Bangladesh
Bangladesh signed an agreement with the Serum Institute of India to purchase 30 million doses of the AstraZeneca vaccine.
It also expects to receive 68 million doses from the GAVI global vaccine alliance at a subsidized rate, a senior Health Ministry official said.
[ad_2]
